Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Factors associated with prolonged progression‐free survival of patients treated with first‐line afatinib for advanced epidermal growth factor receptor‐mutated non‐small cell lung cancer

Abstract Background This study aimed to investigate the factors associated with prolonged progression‐free survival (PFS) (>36 months) of advanced non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR) mutations treated with first‐line afatinib. Methods We p...

Full description

Bibliographic Details
Main Authors: Li‐Chung Chiu, Ping‐Chih Hsu, Chin‐Chou Wang, How‐Wen Ko, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Pi‐Hung Tung, Allen Chung‐Cheng Huang, Cheng‐Ta Yang
Format: Article
Language:English
Published: Wiley 2024-03-01
Series:Thoracic Cancer
Subjects:
afatinib
epidermal growth factor receptor mutation
non‐small cell lung cancer
progression‐free survival
Online Access:https://doi.org/10.1111/1759-7714.15212

Internet

https://doi.org/10.1111/1759-7714.15212

Similar Items